Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine at 12 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants Having Received Hepatitis B Vaccine at Birth
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Hib-DTaP-hepatitis B vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Poliovirus vaccine live oral
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 22 Jan 2010 Actual number of patients (1843) added as reported by ClinicalTrials.gov record.
- 22 Jan 2010 Actual end date (1 Apr 2009) added as reported by ClinicalTrials.gov record.
- 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.